Eli Lilly says it could pull tens of millions of dollars invested in Australian clinical trials unless the federal government dramatically cuts the time it takes to put new drugs onto the Pharmaceutical Benefits Scheme.

The warning from one of the drugmaker’s top executives, visiting Australia this week, builds on pressure from the powerful pharmaceutical lobby for better deals for the medicines they sell domestically and comes at the same time as Donald Trump prepares to place tariffs on drug imports.